You are here

Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis

Last updated on May 11, 2018

FOR MORE INFORMATION
Study Location
Mexico City, D.f., Mexico
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female >18 years of age at time of enrollment

- Clinical diagnosis of stable plaque type psoriasis

- Two target plaques of similar severity meeting the following criteria:

- 5 cm2 and ≤ 100 cm2, computed by multiplying the greatest diameter of the plaque
by the diameter of the plaque perpendicular to the greatest diameter Bilaterally
located (right/left) plaques on the arms or plaques located on the trunk. Plaques
located on the trunk must be separated by at least 10 cm Overall target plaque
severity score (OTPSS) of 2-4 (mild to moderate) with no more than a 1 point
difference in the scores of the two target plaques

- Willing and able to apply study drug as directed, comply with study instructions and
commit to all follow-up visits

- Ability to understand, agree to and sign the study Informed Consent Form (ICF) prior
to initiation of any protocol related procedures

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Any dermatological conditions, disease state or physical condition that could
interfere with clinical evaluations or might expose the patient to an unacceptable
risk by study participation

- Any underlying disease(s) or other dermatological conditions that require the use of
exclusionary topical or systemic therapy (see below)

- Clinically significant, abnormal Screening laboratory results (unless approved by the
medical monitor)

- Known sensitivity to any of the components of the study medication

- Spontaneously improving or rapidly deteriorating psoriatic plaques or
pustular/exfoliative, guttate, erythrodermic or other non-plaque form of psoriasis

- Concomitant use of topical or systemic therapies that might alter the course of
psoriasis

- Females of child bearing potential. Females must be post-menopausal (based on FSH
levels) or surgically sterile (hysterectomy or bilateral oophorectomy)

- Washout periods for exclusionary therapies:

Oral retinoids: 8 weeks Non-retinoid systemic drugs that might alter the course of
psoriasis: 4 weeks Psoralens with UV-A (PUVA): 4 weeks Ultraviolet-B (UVB) therapy: 4 weeks
Topical drugs that might alter the course of psoriasis: 2 weeks Use of
emollients/moisturizers on area(s) to be treated: 2 days prior to Baseline visit

- AIDS or AIDS-related illness

- Concurrent participation in another drug or device research study or within 30 days
prior to enrollment

- Use of lithium- or hydroxychloroquine-containing products (e.g., Plaquenil)

- Use of a beta-blocking medication (e.g., Propranolol) if the dose has not been
stabilized for at least 3 months

- Use of AN2728 in a previous clinical trial

NCT01029405
Pfizer
Completed
Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Rheumatoid Arthritis, Psoriasis Arthritis
NCT01623752
All Genders
Chronic Plaque Psoriasis
NCT02969018
All Genders
18+
Years
Multiple Sites
Psoriatic Arthritis, Psoriasis, Papulosquamous Skin Diseases
NCT00293722
All Genders
18+
Years
Toerwang-Samerberg,
Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis
A Double-Blind,Randomized, 12 Week, Bilateral Study of the Safety and Efficacy of AN2728 Ointment B, 2% and 0.5%, Versus Ointment B Vehicle in the Treatment of Patients With Plaque Type Psoriasis
The purpose of this study is to evaluate the safety and efficacy of AN2728 Ointment B, 2.0% and 0.5%, compared to Ointment Vehicle B, applied once or twice daily for 12 weeks, in the treatment of plaque type psoriasis
This is a multicenter, randomized, double-blind, vehicle-controlled, bilateral design. Patients will apply both test article AN2728 Ointment B (0.5% or 2%), and Ointment B Vehicle twice daily for 12 weeks. The assigned study medication will be applied to two comparable treatment targeted plaques identified at baseline. One test article will be applied to one plaque and the other test article to an anatomically distinct plaque. All efficacy evaluations will be measured from only the two plaques identified at the baseline visit.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Psoriasis
  • Drug: AN2728
    Ointment B, 2% or 0.5% applied once or twice daily
  • Drug: Placebo
    Ointment B Vehicle applied once or twice daily
  • Active Comparator: 1. AN2728 Ointment B
    2%, administered twice daily
    Intervention: Drug: AN2728
  • Placebo Comparator: 2. AN2728 Ointment B Vehicle
    Intervention: Drug: Placebo
  • Active Comparator: 3. AN2728 Ointment B
    2%, administered once daily
    Intervention: Drug: AN2728
  • Active Comparator: 4. AN2728 Ointment B
    0.5%, administered twice daily
    Intervention: Drug: AN2728
  • Active Comparator: 5. AN2728 Ointment B
    0.5%, administered once daily
    Intervention: Drug: AN2728
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
145
June 2010
May 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female >18 years of age at time of enrollment
  • Clinical diagnosis of stable plaque type psoriasis
  • Two target plaques of similar severity meeting the following criteria:

    • 5 cm2 and ? 100 cm2, computed by multiplying the greatest diameter of the plaque by the diameter of the plaque perpendicular to the greatest diameter Bilaterally located (right/left) plaques on the arms or plaques located on the trunk. Plaques located on the trunk must be separated by at least 10 cm Overall target plaque severity score (OTPSS) of 2-4 (mild to moderate) with no more than a 1 point difference in the scores of the two target plaques
  • Willing and able to apply study drug as directed, comply with study instructions and commit to all follow-up visits
  • Ability to understand, agree to and sign the study Informed Consent Form (ICF) prior to initiation of any protocol related procedures

Exclusion Criteria:

  • Any dermatological conditions, disease state or physical condition that could interfere with clinical evaluations or might expose the patient to an unacceptable risk by study participation
  • Any underlying disease(s) or other dermatological conditions that require the use of exclusionary topical or systemic therapy (see below)
  • Clinically significant, abnormal Screening laboratory results (unless approved by the medical monitor)
  • Known sensitivity to any of the components of the study medication
  • Spontaneously improving or rapidly deteriorating psoriatic plaques or pustular/exfoliative, guttate, erythrodermic or other non-plaque form of psoriasis
  • Concomitant use of topical or systemic therapies that might alter the course of psoriasis
  • Females of child bearing potential. Females must be post-menopausal (based on FSH levels) or surgically sterile (hysterectomy or bilateral oophorectomy)
  • Washout periods for exclusionary therapies:

Oral retinoids: 8 weeks Non-retinoid systemic drugs that might alter the course of psoriasis: 4 weeks Psoralens with UV-A (PUVA): 4 weeks Ultraviolet-B (UVB) therapy: 4 weeks Topical drugs that might alter the course of psoriasis: 2 weeks Use of emollients/moisturizers on area(s) to be treated: 2 days prior to Baseline visit

  • AIDS or AIDS-related illness
  • Concurrent participation in another drug or device research study or within 30 days prior to enrollment
  • Use of lithium- or hydroxychloroquine-containing products (e.g., Plaquenil)
  • Use of a beta-blocking medication (e.g., Propranolol) if the dose has not been stabilized for at least 3 months
  • Use of AN2728 in a previous clinical trial
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Mexico
 
 
NCT01029405
AN2728-PSR-203
C3291016 ( Other Identifier: Pfizer )
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
January 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now